

Novacyt SA

06:47 21 Dec 2020

Market Report: FTSE dives as Europe shuts its doors to UK

FTSE 100 opened sharply lower as Britain found itself in near isolation due to concern over the new strain of coronavirus in southern England. The blue-chip index dropped 67 to 6,462.

Ports have been closed because of the new outbreak with lorries 'stacked' up on the road to Dover due to a ban on freight by France. Flights and trains to many parts of Europe have been halted with the UK cabinet committee Cobra holding an emergency meeting about the situation.

Shares in British Airways owner IAG tumbled by almost 18%. Retailers reacted with dismay to the new clampdown imposed yesterday in the south-east due to the spike in infections. Mike Ashley's Frasers Group, which owns Sports Direct, withdrew profits guidance as most of its shops in the region were now shut it said.

Elsewhere, Shell said it will write down the value of oil and gas assets by a further US\$3.5bn to US\$4.5bn due to the uncertain backdrop. The Anglo-Dutch oil giant took a US\$16.8bn write-down earlier this year.

Among the small caps, Novacyt (LON:NCYT) confirmed its tests can detect the new COVID-19 strain found in the UK. The level of accuracy remains the same, according to a computer simulation.

Symphony Environmental Technologies PLC (LON:SYM) is starting legal action against the EU in relation to new rules to ban a certain type of plastic. The biodegradable plastic specialist deems the regulation confusing and illegal.

Guild Esports PLC (LON:GILD) has signed Henrik Mclean, a top-ranked professional esports player, to its Fortnite team. 15-year-old Mclean will also play in other games such as Valorant, Rocket League and FIFA.

Price: 679.36

Market Cap: £479.81 m

1 Year Share Price Graph



March 2020 September 2020 March 2021

Share Information

Code: NCYT

Listing: AIM

52 week	High	Low
	1276	97.0001

Sector: Pharma & Biotech

Website: novacyt.com

Company Synopsis:

AIM-listed Novacyt operates in the field of cellular diagnostics, with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform Novaprep and a strong international network, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.